Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
We hypothesized that specific activation of a single retinoic acid receptor-alpha (RARalpha), without direct and concurrent activation of RARbeta and gamma, will inhibit mammary tumor oncogenesis in murine models relevant to human cancer.
|
20453882 |
2010 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aberrant expression of retinoic acid receptor-α (RARα) has been reported in various types of cancer.
|
29344234 |
2017 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Acute promyelocytic leukaemia (APL) driven by chimeric transcription factors encoding retinoic acid receptor alpha fusions is the paradigm of targeted cancer therapy, in which the application of all-trans retinoic acid (ATRA) treatments have markedly transformed this highly fatal cancer to a highly manageable disease.
|
25247321 |
2015 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, the restoration of RAR-beta2 expression inhibits tumor cell growth and suppresses cancer development.
|
16849557 |
2006 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia.
|
18941112 |
2009 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Indeed, mutant oncogenes (EGFR, HER2, RAS, MET, PML-RARα) are known to alter the expression of angiogenic and pro-inflammatory factors, as well as change the cancer cell coagulome, including the levels of tissue factor (TF) and other mediators (PAI-1, COX2).
|
22682129 |
2012 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here we show that anticancer and cancer-promoting RA actions in breast cancer have roots in a mechanism of mammary epithelial cell morphogenesis that involves both transcriptional (epigenetic) and non-transcriptional RARα (RARA) functions.
|
27894085 |
2016 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Estradiol-mediated enhancement of retinoic acid receptor alpha (RARalpha) expression in the estrogen receptor (ER)-positive human breast carcinoma (HBC) cells results in their sensitivity to RA-mediated growth inhibition (A. K. Rishi et al., Cancer Res., 55: 4999-5006, 1995).
|
8912864 |
1996 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The balanced chromosomal translocation t(15;17)(q22;q12-21) of this malignancy is now known to involve the nuclear retinoic acid receptor-alpha (RAR-alpha) on the long arm of chromosome 17 and a novel gene on the long arm of chromosome 15, designated PML (previously called myl).
|
1323988 |
1992 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunoprecipitation/Western blot analysis showed that, although sumoylated and ubiquitinated RARalpha existed simultaneously in both cancer cell lines, ATRA exerted different regulatory effects on sumoylation and ubiquitination of RARalpha.
|
15171703 |
2004 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The RAR(alpha) gene has drawn particular attention because it is the common target in all chromosomal translocations in acute promyelocytic leukemia (APL), a unique model in cancer research that responds to the effect of RA.
|
12032336 |
2002 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Because these transcription factors play a key role in growth control, some nuclear hormone receptors, such as the retinoic acid receptor alpha, can be disrupted in cancer.
|
9290702 |
1997 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid and/or arsenic trioxide represents a paradigm in targeted cancer therapy because these drugs cause clinical remission by affecting the stability of the fusion oncoprotein promyelocytic leukemia (PML)/retinoic acid receptor alpha (RARA).
|
20574048 |
2010 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
A subset of patients were found to have an SE at <i>RARA</i>, which is predictive for response to SY-1425, a potent and selective RARα agonist, in preclinical models, forming the rationale for its clinical investigation in biomarker-selected patients.<i>Cancer Discov; 7(10); 1136-53.
|
28729405 |
2017 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Acute promyelocytic leukemia (APL), characterized by a translocation between the promyelocytic leukemia gene (PML) on chromosome 15 and the retinoic acid receptor-alpha (RARalpha) gene on chromosome 17, has become a model for targeted treatment of cancer.
|
17706161 |
2007 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, loss, accumulation, mutations or aberrant modifications of a specific RAR lead to uncontrolled proliferation and/or to differentiation block and thereby to cancer.
|
20970498 |
2011 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The authors' analysis led to the discovery of a novel <i>RARA</i> superenhancer found in a subset of patients with AML, rendering these leukemia cells highly sensitive to SY-1425, a highly potent RARA agonist able to induce myeloid differentiation in these high-expressing RARA AML subtypes.<i>Cancer Discov; 7(10); 1065-6.
|
28974530 |
2017 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Acute promyelocytic leukemia (APL) is a human cancer generated by a chromosomal translocation t(15;17) involving the promyelocytic leukemia (PML) and retinoic acid receptor alpha (RARalpha) genes.
|
15988048 |
2005 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Using a human mammary MCF7-derived AREc32 reporter cell line, we now report that all-trans retinoic acid (ATRA), and other retinoic acid receptor alpha (RARalpha) agonists, markedly reduces the ability of Nrf2 to mediate induction of ARE-driven genes by cancer chemopreventive agents including the metabolite of butylated hydroxyanisole, tert-butylhydroquinone (tBHQ).
|
18048326 |
2007 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RAR-beta2 mRNA expression was significantly reduced (i.e., lower in cancer than normal tissue) in 67% (18 of 27, P = 0.001) and RAR-beta(4) mRNA was increased in 52% (14 of 27, P = 0.054) of our esophageal cancer cases.
|
15824151 |
2005 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
These results strongly suggest that XAB2 is a component of the RAR corepressor complex with an inhibitory effect on ATRA-induced cellular differentiation and that XAB2 plays a role in ATRA-mediated cellular differentiation as an important aspect of cancer therapy.
|
17283134 |
2007 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SP1 and RARα regulate AGAP2 expression in cancer.
|
30674964 |
2019 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In this issue of Cancer Cell, studies by Kwok et al. and Sternsdorf et al. indicate that the ability of the RARalpha oncoproteins to dimerize/multimerize is an essential feature required for the development of disease.
|
16473273 |
2006 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
<i>TBL1XR1-RARB</i> as an oncogenic protein exerts effects similar to those of <i>PML-RARA</i>, underpinning the importance of retinoic acid pathway alterations in the pathogenesis of APL.<b>Significance:</b> These findings report a novel and distinct genetic subtype of acute promyelocytic leukemia (APL) by illustrating that the majority of APL without RARA translocations harbor RARB translocations.<i>Cancer Res; 78(16); 4452-8.©2018 AACR</i>.
|
29921692 |
2018 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the randomised, controlled, multicentre, AML17 trial, eligible patients (aged ≥16 years) with acute promyelocytic leukaemia, confirmed by the presence of the PML-RARA transcript and without significant cardiac or pulmonary comorbidities or active malignancy, and who were not pregnant or breastfeeding, were enrolled from 81 UK hospitals and randomised 1:1 to receive treatment with ATRA and arsenic trioxide or ATRA and idarubicin.
|
26384238 |
2015 |